MIMETAS Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 80

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 10

MIMETAS General Information

Description

Developer of organ-on-a-chip technology designed for drug discovery and human tissue modeling. The company produces microfluidic titer plates and three-dimensional tissue models that support continuous perfusion and high-throughput screening, enabling pharmaceutical companies to utilize high-fidelity human tissue models to predict drug responses and safety profiles more accurately than traditional animal models.

Contact Information

Website
www.mimetas.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biopartner Building 5
  • De Limes 7
  • 2342 DH Oegstgeest
  • Netherlands
+31 085
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Biopartner Building 5
  • De Limes 7
  • 2342 DH Oegstgeest
  • Netherlands
+31 085

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MIMETAS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 10-Aug-2026 Completed Generating Revenue
13. Secondary Transaction - Private 01-Jun-2026 Completed Generating Revenue
12. Accelerator/Incubator 12-Apr-2022 Completed Generating Revenue
11. Grant 28-Sep-2020 Completed Generating Revenue
10. Later Stage VC 26-Feb-2020 Completed Generating Revenue
9. Later Stage VC (Series B) 11-Apr-2018 Completed Generating Revenue
8. Grant 01-Jan-2016 Completed Generating Revenue
7. Grant 22-Dec-2015 Completed Generating Revenue
6. Early Stage VC (Series A) 08-Oct-2014 $7.15M $8.91M Completed Generating Revenue
5. Seed Round 11-Sep-2014 $1.76M $1.76M Completed Generating Revenue
To view MIMETAS’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

MIMETAS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of organ-on-a-chip technology designed for drug discovery and human tissue modeling. The company produces micr
Discovery Tools (Healthcare)
Oegstgeest, Netherlands
80 As of 2026

Saint-Sulpice, Switzerland
 

Orlando, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MIMETAS Competitors (30)

One of MIMETAS’s 30 competitors is Nagi Bioscience, a Venture Capital-Backed company based in Saint-Sulpice, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nagi Bioscience Venture Capital-Backed Saint-Sulpice, Switzerland
Hesperos Venture Capital-Backed Orlando, FL
28bio Venture Capital-Backed New Orleans, LA
Miltenyi Biotec Private Debt Financed Bergisch Gladbach, Germany
FUJIFILM Cellular Dynamics Formerly VC-backed Madison, WI
You’re viewing 5 of 30 competitors. Get the full list »

MIMETAS Patents

  • 71

    Total Documents Applications and Grants

  • Total Patents Families

  • 37

    Granted

  • 18

    Pending

  • Expiring in next 12 mo

MIMETAS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024337635-A1 Titerplate Pending 08-Sep-2023
EP-4774364-A1 Titerplate Pending 08-Sep-2023
WO-2025051969-A1 Titerplate Inactive 08-Sep-2023
JP-2026508594-A Hepatic vasculature Pending 13-Mar-2023
EP-4680962-A1 Liver vasculature Pending 13-Mar-2023 C12N5/067
To view MIMETAS’s complete patent history, request access »

MIMETAS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MIMETAS Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bruker Corporation Minority
European Innovation Council Accelerator/Incubator
National Institutes of Health Government
Gold Nest Capital Venture Capital Minority
KIKK Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

MIMETAS FAQs

  • When was MIMETAS founded?

    MIMETAS was founded in 2013.

  • Where is MIMETAS headquartered?

    MIMETAS is headquartered in Oegstgeest, Netherlands.

  • What is the size of MIMETAS?

    MIMETAS has 80 total employees.

  • What industry is MIMETAS in?

    MIMETAS’s primary industry is Discovery Tools (Healthcare).

  • Is MIMETAS a private or public company?

    MIMETAS is a Private company.

  • What is MIMETAS’s current revenue?

    The current revenue for MIMETAS is .

  • How much funding has MIMETAS raised over time?

    MIMETAS has raised $29.4M.

  • Who are MIMETAS’s investors?

    Bruker, European Innovation Council, National Institutes of Health, Gold Nest Capital, and KIKK Capital are 5 of 10 investors who have invested in MIMETAS.

  • Who are MIMETAS’s competitors?

    Nagi Bioscience, Hesperos, 28bio, Miltenyi Biotec, and FUJIFILM Cellular Dynamics are some of the 30 competitors of MIMETAS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process